Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary:
1. To compare the change in forearm vascular resistance following a 12-week regimen of
irbesartan/hydrochlorothiazide versus irbesartan
2. To assess changes of serum proinflammatory cytokine, markers of cardiovascular risks,
oxidative stress and circulating adhesion molecule including thiobarbiturate acid
reactive substances (TBARS), C-reactive protein (CRP), interleukin 6 (IL-6), and
vascular cell adhesion molecule 1 (VCAM-1).
Secondary:
1. To compare the reduction in office blood pressure following a 12-week regimen of
irbesartan/hydrochlorothiazide versus irbesartan
2. To compare the response rate (defined as office Systolic blood pressure(SBP)/diastolic
blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate
(defined as SBP<140 mmHg and /or DBP<90 mmHg)
3. To ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus
irbesartan when administered once daily
4. To determine whether angiotensin II type 1 (AT-1) receptor gene polymorphisms (including
A1166C gene with about 4% of the minor allele frequency in Chinese population and other
single nucleotide polymorphisms with a higher frequency of about 10% of minor allele) is
related to reduction of BP